BioPharma Systems — Selling and administrative expense
Becton, Dickinson and Company BioPharma Systems — Selling and administrative expense decreased by 97.4% to $32.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 97.1%, from $1.12B to $32.00M. Over 4 years (FY 2021 to FY 2026), BioPharma Systems — Selling and administrative expense shows a downward trend with a -13.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase may reflect strategic investments in sales force expansion or higher administrative overhead.
Detailed definition
This metric captures the operating expenses related to the sales, marketing, and general administrative functions specif...
Peer comparison
Comparable to SG&A expense allocations in business units of diversified medical technology companies.
bdx_segment_biopharma_systems_selling_and_administrative_expenseHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.20B | $1.22B | $1.19B | $1.19B | $1.15B | $1.18B | $1.19B | $1.21B | $1.19B | $1.14B | $1.21B | $1.19B | $1.20B | $1.26B | $1.32B | $29.00M | $1.12B | $28.00M | $1.32B | $1.52B | $1.39B | $29.00M | $1.21B | $32.00M |
| QoQ Change | — | +1.8% | -3.0% | +0.6% | -3.6% | +3.0% | +0.3% | +1.5% | -1.2% | -4.5% | +6.7% | -1.6% | +0.3% | +4.9% | +5.0% | -97.8% | >999% | -97.5% | >999% | +15.4% | -8.5% | -97.9% | >999% | -97.4% |
| YoY Change | — | — | — | — | -4.3% | -3.2% | +0.2% | +1.1% | +3.6% | -3.9% | +2.2% | -1.0% | +0.5% | +10.4% | +8.7% | -97.6% | -6.4% | -97.7% | +10.4% | +21.4% | +5.7% | -97.8% | +8.6% | -97.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's biopharma systems — selling and administrative expense?
- Becton, Dickinson and Company (BDX) reported biopharma systems — selling and administrative expense of $32.00M in Q1 2026.
- How has Becton, Dickinson and Company's biopharma systems — selling and administrative expense changed year-over-year?
- Becton, Dickinson and Company's biopharma systems — selling and administrative expense decreased by 97.1% year-over-year, from $1.12B to $32.00M.
- What is the long-term trend for Becton, Dickinson and Company's biopharma systems — selling and administrative expense?
- Over 4 years (2021 to 2026), Becton, Dickinson and Company's biopharma systems — selling and administrative expense has grown at a -13.3% compound annual growth rate (CAGR), from $4.72B to $2.67B.
- What does biopharma systems — selling and administrative expense mean?
- Operating costs for sales, marketing, and administration within the BioPharma Systems segment.